Browse CGN

Summary
SymbolCGN
Namecingulin
Aliases KIAA1319
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell junction, tight junction Note=Localizes to the apical junction complex composed of tight and adherens junctions.
Domain PF01576 Myosin tail
Function

Probably plays a role in the formation and regulation of the tight junction (TJ) paracellular permeability barrier.

> Gene Ontology
 
Biological Process GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
Molecular Function GO:0003774 motor activity
GO:0003779 actin binding
GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0005913 cell-cell adherens junction
GO:0005923 bicellular tight junction
GO:0015629 actin cytoskeleton
GO:0016459 myosin complex
GO:0043296 apical junction complex
GO:0070160 occluding junction
> KEGG and Reactome Pathway
 
KEGG hsa04530 Tight junction
Reactome R-HSA-162582: Signal Transduction
R-HSA-170834: Signaling by TGF-beta Receptor Complex
R-HSA-2173791: TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
Summary
SymbolCGN
Namecingulin
Aliases KIAA1319
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CGN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCGN
Namecingulin
Aliases KIAA1319
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CGN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCGN
Namecingulin
Aliases KIAA1319
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CGN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.5420.194
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.860.286
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3270.56
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6790.249
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.0340.634
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2350.934
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.9010.265
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.6010.163
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0060.996
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3860.676
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2880.806
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.6120.00778
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CGN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.42.74.70.294
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.43.440.587
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.511.8-2.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 1113015.4-15.40.482
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512016.7-16.71
Summary
SymbolCGN
Namecingulin
Aliases KIAA1319
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CGN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCGN
Namecingulin
Aliases KIAA1319
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CGN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CGN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCGN
Namecingulin
Aliases KIAA1319
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CGN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCGN
Namecingulin
Aliases KIAA1319
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CGN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCGN
Namecingulin
Aliases KIAA1319
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CGN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCGN
Namecingulin
Aliases KIAA1319
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CGN collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.